Horowitz Limited Partnership VIII 3
3 · Tarsus Pharmaceuticals, Inc. · Filed Oct 15, 2020
Insider Transaction Report
Form 3
Horowitz Limited Partnership VIII
10% Owner
Holdings
Series A Preferred Stock
[F1]→ Common Stock (1,434,790 underlying)Series B Preferred Stock
[F2]→ Common Stock (245,966 underlying)Series C Preferred Stock
[F3]→ Common Stock (71,427 underlying)- (indirect: By Trust)
Series A Preferred Stock
[F1][F4]→ Common Stock (43,151 underlying) - (indirect: By Trust)
Series B Preferred Stock
[F2][F4]→ Common Stock (7,396 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
- [F2]The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F3]The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.
- [F4]The shares are held by the Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.
Signature
/s/ Jason Tester, as Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII|2020-10-15